180 related articles for article (PubMed ID: 35378764)
21. Structural and biochemical mechanism for increased infectivity and immune evasion of Omicron BA.2 variant compared to BA.1 and their possible mouse origins.
Xu Y; Wu C; Cao X; Gu C; Liu H; Jiang M; Wang X; Yuan Q; Wu K; Liu J; Wang D; He X; Wang X; Deng SJ; Xu HE; Yin W
Cell Res; 2022 Jul; 32(7):609-620. PubMed ID: 35641567
[TBL] [Abstract][Full Text] [Related]
22. Anatomy of Omicron BA.1 and BA.2 neutralizing antibodies in COVID-19 mRNA vaccinees.
Andreano E; Paciello I; Marchese S; Donnici L; Pierleoni G; Piccini G; Manganaro N; Pantano E; Abbiento V; Pileri P; Benincasa L; Giglioli G; Leonardi M; Maes P; De Santi C; Sala C; Montomoli E; De Francesco R; Rappuoli R
Nat Commun; 2022 Jun; 13(1):3375. PubMed ID: 35697673
[TBL] [Abstract][Full Text] [Related]
23. A potent synthetic nanobody with broad-spectrum activity neutralizes SARS-CoV-2 virus and the Omicron variant BA.1 through a unique binding mode.
Zhao D; Liu L; Liu X; Zhang J; Yin Y; Luan L; Jiang D; Yang X; Li L; Xiong H; Xing D; Zheng Q; Xia N; Tao Y; Li S; Huang H
J Nanobiotechnology; 2022 Sep; 20(1):411. PubMed ID: 36109732
[TBL] [Abstract][Full Text] [Related]
24. Nanobodies Protecting From Lethal SARS-CoV-2 Infection Target Receptor Binding Epitopes Preserved in Virus Variants Other Than Omicron.
Casasnovas JM; Margolles Y; Noriega MA; Guzmán M; Arranz R; Melero R; Casanova M; Corbera JA; Jiménez-de-Oya N; Gastaminza P; Garaigorta U; Saiz JC; Martín-Acebes MÁ; Fernández LÁ
Front Immunol; 2022; 13():863831. PubMed ID: 35547740
[TBL] [Abstract][Full Text] [Related]
25. Computationally Designed ACE2 Decoy Receptor Binds SARS-CoV-2 Spike (S) Protein with Tight Nanomolar Affinity.
Havranek B; Chan KK; Wu A; Procko E; Islam SM
J Chem Inf Model; 2021 Sep; 61(9):4656-4669. PubMed ID: 34427448
[TBL] [Abstract][Full Text] [Related]
26. Heterogeneous Infectivity and Pathogenesis of SARS-CoV-2 Variants Beta, Delta and Omicron in Transgenic K18-hACE2 and Wildtype Mice.
Tarrés-Freixas F; Trinité B; Pons-Grífols A; Romero-Durana M; Riveira-Muñoz E; Ávila-Nieto C; Pérez M; Garcia-Vidal E; Perez-Zsolt D; Muñoz-Basagoiti J; Raïch-Regué D; Izquierdo-Useros N; Andrés C; Antón A; Pumarola T; Blanco I; Noguera-Julián M; Guallar V; Lepore R; Valencia A; Urrea V; Vergara-Alert J; Clotet B; Ballana E; Carrillo J; Segalés J; Blanco J
Front Microbiol; 2022; 13():840757. PubMed ID: 35602059
[TBL] [Abstract][Full Text] [Related]
27. LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants.
Westendorf K; Žentelis S; Wang L; Foster D; Vaillancourt P; Wiggin M; Lovett E; van der Lee R; Hendle J; Pustilnik A; Sauder JM; Kraft L; Hwang Y; Siegel RW; Chen J; Heinz BA; Higgs RE; Kallewaard NL; Jepson K; Goya R; Smith MA; Collins DW; Pellacani D; Xiang P; de Puyraimond V; Ricicova M; Devorkin L; Pritchard C; O'Neill A; Dalal K; Panwar P; Dhupar H; Garces FA; Cohen CA; Dye JM; Huie KE; Badger CV; Kobasa D; Audet J; Freitas JJ; Hassanali S; Hughes I; Munoz L; Palma HC; Ramamurthy B; Cross RW; Geisbert TW; Menacherry V; Lokugamage K; Borisevich V; Lanz I; Anderson L; Sipahimalani P; Corbett KS; Yang ES; Zhang Y; Shi W; Zhou T; Choe M; Misasi J; Kwong PD; Sullivan NJ; Graham BS; Fernandez TL; Hansen CL; Falconer E; Mascola JR; Jones BE; Barnhart BC
bioRxiv; 2022 Mar; ():. PubMed ID: 33972947
[TBL] [Abstract][Full Text] [Related]
28. Using host receptor as a decoy to treat COVID-19: a solution for immune escape?
Huang KY; Lin MS; Yang PC
EMBO Mol Med; 2022 Nov; 14(11):e16818. PubMed ID: 36256519
[TBL] [Abstract][Full Text] [Related]
29. Engineered ACE2 decoy mitigates lung injury and death induced by SARS-CoV-2 variants.
Zhang L; Dutta S; Xiong S; Chan M; Chan KK; Fan TM; Bailey KL; Lindeblad M; Cooper LM; Rong L; Gugliuzza AF; Shukla D; Procko E; Rehman J; Malik AB
Nat Chem Biol; 2022 Mar; 18(3):342-351. PubMed ID: 35046611
[TBL] [Abstract][Full Text] [Related]
30. Patient-derived monoclonal antibody neutralizes SARS-CoV-2 Omicron variants and confers full protection in monkeys.
Fenwick C; Turelli P; Ni D; Perez L; Lau K; Herate C; Marlin R; Lana E; Pellaton C; Raclot C; Esteves-Leuenberger L; Campos J; Farina A; Fiscalini F; Dereuddre-Bosquet N; Relouzat F; Abdelnabi R; Foo CS; Neyts J; Leyssen P; Lévy Y; Pojer F; Stahlberg H; LeGrand R; Trono D; Pantaleo G
Nat Microbiol; 2022 Sep; 7(9):1376-1389. PubMed ID: 35879526
[TBL] [Abstract][Full Text] [Related]
31. Structural Study of SARS-CoV-2 Antibodies Identifies a Broad-Spectrum Antibody That Neutralizes the Omicron Variant by Disassembling the Spike Trimer.
Zhan W; Tian X; Zhang X; Xing S; Song W; Liu Q; Hao A; Hu Y; Zhang M; Ying T; Chen Z; Lan F; Sun L
J Virol; 2022 Aug; 96(16):e0048022. PubMed ID: 35924918
[TBL] [Abstract][Full Text] [Related]
32. Comparative Binding Ability of Human Monoclonal Antibodies against Omicron Variants of SARS-CoV-2: An
Das NC; Chakraborty P; Bayry J; Mukherjee S
Antibodies (Basel); 2023 Feb; 12(1):. PubMed ID: 36975364
[TBL] [Abstract][Full Text] [Related]
33. Antibody affinity and cross-variant neutralization of SARS-CoV-2 Omicron BA.1, BA.2 and BA.3 following third mRNA vaccination.
Bellusci L; Grubbs G; Zahra FT; Forgacs D; Golding H; Ross TM; Khurana S
Nat Commun; 2022 Aug; 13(1):4617. PubMed ID: 35941152
[TBL] [Abstract][Full Text] [Related]
34. Role of spike in the pathogenic and antigenic behavior of SARS-CoV-2 BA.1 Omicron.
Chen DY; Kenney D; Chin CV; Tavares AH; Khan N; Conway HL; Liu G; Choudhary MC; Gertje HP; O'Connell AK; Kotton DN; Herrmann A; Ensser A; Connor JH; Bosmann M; Li JZ; Gack MU; Baker SC; Kirchdoerfer RN; Kataria Y; Crossland NA; Douam F; Saeed M
bioRxiv; 2023 Jan; ():. PubMed ID: 36263066
[TBL] [Abstract][Full Text] [Related]
35. The Omicron Variant BA.1.1 Presents a Lower Pathogenicity than B.1 D614G and Delta Variants in a Feline Model of SARS-CoV-2 Infection.
Martins M; do Nascimento GM; Nooruzzaman M; Yuan F; Chen C; Caserta LC; Miller AD; Whittaker GR; Fang Y; Diel DG
J Virol; 2022 Sep; 96(17):e0096122. PubMed ID: 36000850
[TBL] [Abstract][Full Text] [Related]
36. The Omicron variant BA.1.1 presents a lower pathogenicity than B.1 D614G and Delta variants in a feline model of SARS-CoV-2 infection.
Martins M; do Nascimento GM; Nooruzzaman M; Yuan F; Chen C; Caserta LC; Miller AD; Whittaker GR; Fang Y; Diel DG
bioRxiv; 2022 Jun; ():. PubMed ID: 35734088
[TBL] [Abstract][Full Text] [Related]
37. ACE2 decoy Fc-fusions and bi-specific killer engager (BiKEs) require Fc engagement for
Dick JK; Hicks D; Krishna VD; Sangala JA; Zandstra BT; Baehr C; Verbeek JS; Cragg MS; Cheeran MC; Pravetoni M; Hart GT
bioRxiv; 2024 Jun; ():. PubMed ID: 38948747
[TBL] [Abstract][Full Text] [Related]
38. Human serum from SARS-CoV-2-vaccinated and COVID-19 patients shows reduced binding to the RBD of SARS-CoV-2 Omicron variant.
Schubert M; Bertoglio F; Steinke S; Heine PA; Ynga-Durand MA; Maass H; Sammartino JC; Cassaniti I; Zuo F; Du L; Korn J; Milošević M; Wenzel EV; Krstanović F; Polten S; Pribanić-Matešić M; Brizić I; Baldanti F; Hammarström L; Dübel S; Šustić A; Marcotte H; Strengert M; Protić A; Piralla A; Pan-Hammarström Q; Čičin-Šain L; Hust M
BMC Med; 2022 Mar; 20(1):102. PubMed ID: 35236358
[TBL] [Abstract][Full Text] [Related]
39. Potency of Fusion-Inhibitory Lipopeptides against SARS-CoV-2 Variants of Concern.
Schmitz KS; Geers D; de Vries RD; Bovier TF; Mykytyn AZ; Geurts van Kessel CH; Haagmans BL; Porotto M; de Swart RL; Moscona A
mBio; 2022 Jun; 13(3):e0124922. PubMed ID: 35695453
[TBL] [Abstract][Full Text] [Related]
40. Structural Basis for Human Receptor Recognition by SARS-CoV-2 Omicron Variant BA.1.
Geng Q; Shi K; Ye G; Zhang W; Aihara H; Li F
J Virol; 2022 Apr; 96(8):e0024922. PubMed ID: 35343765
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
